Safety, efficacy, and biological data of T cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial.

Santeri A Pakola Katriina J Peltola James H A Clubb Elise Jirovec Lyna Haybout Tatiana Viktorovna Kudling Tuomo Alanko Riitta Korpisaari Susanna M Juteau Marjut Laukka Jorma Sormunen Jukka Kemppainen Annabrita Hemmes Teijo Pellinen Mirte van der Heijden Dafne C A Quixabeira Claudia Kistler Suvi Sorsa Riikka Havunen Joao M Santos Victor Cervera-Carrascon Akseli E Hemminki

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

TILT-123 was safe and able to produce anti-tumor effects in local and distant lesions in heavily pre-treated patients. Good tolerability of TILT-123 facilitates combination studies, several of which are ongoing (NCT04217473, NCT05271318, NCT05222932, NCT06125197).

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
clinical trial
prognostic factors
lymph node
study protocol
randomized controlled trial
big data
machine learning
phase ii
case control
free survival